PMS Treatment Market to Reach $1.91B by 2033 from $1.39B in 2024

Premenstrual Syndrome (PMS) Treatment Market Size, Trends, and Forecast (2025–2033)

According to Renub Research, the Premenstrual Syndrome (PMS) Treatment Market is set to expand from US$ 1,385.44 million in 2024 to US$ 1,909.67 million by 2033, reflecting a steady CAGR of 3.63% during the forecast period. Growth is supported by rising awareness of women’s health, a higher prevalence of PMS and PMDD, advances in therapeutic options, and broader access to healthcare services worldwide. As PMS becomes more openly discussed and clinically addressed, demand for reliable treatment solutions continues to surge across both developed and emerging economies.

Market Overview

Premenstrual Syndrome refers to a cluster of physical, emotional, and behavioral symptoms that occur in the luteal phase of the menstrual cycle. Effective PMS treatment encompasses hormonal therapies, selective serotonin reuptake inhibitors (SSRIs), analgesics, NSAIDs, diuretics, and a growing array of supplements, vitamins, herbal remedies, lifestyle programs, and integrative care options.

Over the past decade, the global healthcare community has placed greater emphasis on women’s reproductive health. This shift, combined with the destigmatization of menstrual and hormonal issues, has driven women to seek medical advice for moderate to severe PMS symptoms. Healthcare professionals now advocate for early diagnosis, individualized medication plans, and combination therapies. Parallel to pharmaceutical growth, the widespread availability of OTC products, e-commerce pharmacy channels, and teleconsultation services supports broader access to treatment.

As consumer behavior evolves, PMS management is increasingly seen not only as a therapeutic need but also as part of a broader lifestyle and wellness movement. This creates opportunities for both established pharmaceutical companies and emerging women’s health brands.

Request a free sample copy of the report:https://www.renub.com/request-sample-page.php?gturl=premenstrual-syndrome-treatment-market-p.php

Key Market Drivers

1. Rising Awareness and Education on Women’s Health

Public health initiatives, digital health platforms, social media campaigns, and government programs have substantially improved understanding of PMS and its impact. Educated consumers are more likely to recognize that PMS is treatable and seek professional care instead of tolerating recurring discomfort.

According to the National Institutes of Health (NIH), nearly 75% of women experience some form of PMS, and approximately 5% suffer from Premenstrual Dysphoric Disorder (PMDD)—a severe form of PMS that significantly disrupts daily life. As awareness of PMDD grows, so does the demand for prescription-grade therapies.

2. Advancements in Pharmaceutical and Non-Pharmaceutical Therapies

Research innovations have strengthened the therapeutic landscape:

·       SSRIs and combination oral contraceptives continue to demonstrate strong efficacy.

·       Non-pharmaceutical therapies—including herbal supplements, vitamins, and cognitive-behavioral approaches—are gaining widespread consumer acceptance.

·       Companies are investing in novel treatment pathways, as highlighted by Vistagen’s Phase 2A study (September 2023) showing promising results for PH80, an investigational treatment for PMDD targeting emotional and physical symptoms.

Together, these advancements provide clinicians with a broader toolbox, enabling more tailored and tolerable treatment plans.

3. Improved Healthcare Infrastructure and Urbanization

Emerging economies are rapidly expanding access to women’s healthcare services. Urbanization exposes populations to:

·       Gynecology clinics and specialist care

·       Retail pharmacies and OTC medicines

·       Digital platforms offering online consultation and remote prescriptions

Insurance coverage and rapid telemedicine adoption further help women access therapies conveniently and affordably.

Market Challenges

1. Underdiagnosis in Low-Income and Rural Regions

In many developing countries, cultural stigmas and inadequate healthcare infrastructure limit diagnosis and treatment. Women often dismiss PMS as a normal burden, and few seek medical intervention. This lack of diagnosis restricts the market’s full potential, particularly in rural Asia, Africa, and Latin America.

2. Side Effects and Treatment Compliance

While pharmaceutical treatments are effective, SSRIs, hormonal contraceptives, and NSAIDs may cause:

·       Nausea

·       Weight gain

·       Mood fluctuations

·       Gastrointestinal disturbances

Side effects can reduce adherence, prompting some users to discontinue therapy prematurely. Non-pharmaceutical options tend to have fewer side effects but may not provide comparable relief for severe PMS or PMDD, creating a gap between patient expectations and clinical outcomes.

Segment Analysis

Analgesics

Analgesics—especially NSAIDs—represent one of the fastest-adopted treatment categories for PMS, given their accessibility and role in pain relief. Ibuprofen and naproxen remain household staples for menstrual discomfort. Strong retail and e-commerce availability boosts this segment, making analgesics a reliable revenue generator in both developed and emerging markets.

Prescription PMS Treatments

This segment includes SSRIs, oral contraceptives, diuretics, and specialized agents for PMDD. With diagnoses of PMDD increasing and more women seeking effective long-term relief, the prescription category is poised for robust growth. Pharmaceutical innovation remains strong, exemplified by Vistagen and companies focusing on better hormonal regulation therapies.

Hospital Pharmacies

Hospital pharmacies remain important distribution hubs for advanced or prescription-only treatments. Many women receive their initial PMS or PMDD diagnosis during gynecological visits, and hospital pharmacies fulfill much of this prescription demand. As global hospital infrastructure expands, especially across Asia and the Middle East, this channel will continue to grow.

Regional Analysis

United States

The U.S. leads the PMS treatment market due to its advanced healthcare system, high diagnosis rates, and strong pharmaceutical ecosystem. In March 2024, Pfizer Inc. launched Loryna, a new oral therapy specifically approved by the U.S. FDA for PMDD. Increased awareness, insurance coverage, and diversified retail pharmacy networks continue to drive market momentum.

France

France benefits from progressive women’s health policies and strong access to gynecologists. French women increasingly adopt hormonal therapies and clinically backed non-prescription options. Hospital and retail pharmacy penetration remains high, fostering a stable PMS treatment environment.

China

China’s market is accelerating rapidly due to rising urbanization, improvements in women’s health services, and growing recognition of PMS and PMDD. While traditional remedies and OTC analgesics remain popular, prescription treatments are expanding quickly in urban centers. Government initiatives in women’s healthcare and digital medicine platforms bolster growth.

Brazil

Brazil’s expanding middle class and improving health awareness fuel demand for PMS therapies. Urban pharmacy networks dominate the distribution channel, while telemedicine and home delivery services are helping penetrate underserved regions. Hormonal therapies and analgesics remain top-choice treatments.

Saudi Arabia

Saudi Arabia’s PMS treatment market is benefiting from healthcare modernization under Vision 2030, which emphasizes women's health and access to medical services. Hospital pharmacies dominate prescription distribution, while retail and online pharmacies cater to OTC purchases. Cultural shifts and rising disposable incomes contribute to market expansion.

Market Segmentation Overview

By Drug Type

·       Analgesics

·       Antidepressants

·       Oral Contraceptives & Ovarian Suppression Agents

·       Others

By Type

·       Prescription

·       Over-the-Counter

By Distribution Channel

·       Hospital Pharmacies

·       Retail & Drug Stores

·       Online Pharmacies

By Country

·       North America (U.S., Canada)

·       Europe (France, Germany, Italy, Spain, U.K., Belgium, Netherlands, Turkey)

·       Asia Pacific (China, Japan, India, South Korea, Thailand, Malaysia, Indonesia, Australia, New Zealand)

·       Latin America (Brazil, Mexico, Argentina)

·       Middle East & Africa (Saudi Arabia, UAE, South Africa)

Key Companies Covered

·       AbbVie Inc.

·       BASF SE

·       Bayer AG

·       Dr. Reddy’s Laboratories Ltd

·       Eli Lilly and Company

·       GlaxoSmithKline plc

·       H. Lundbeck A/S

·       Pfizer Inc.

·       SHIONOGI & Co. Ltd.

These companies are analyzed across five viewpoints:

Overview, Key Personnel, Recent Developments, SWOT Analysis, and Revenue Analysis.

Conclusion

The global PMS treatment market is entering a period of sustained growth, supported by strong healthcare awareness, evolving therapeutic options, rising diagnosis rates for PMS and PMDD, and widespread access to retail and digital pharmacy channels. The expected rise from US$ 1,385.44 million in 2024 to US$ 1,909.67 million by 2033 underscores the increasing recognition of PMS as a legitimate, treatable medical condition affecting women’s daily lives, productivity, and overall well-being.

As women’s health continues to gain global attention, the market is poised to benefit from innovations in pharmaceuticals, holistic wellness, precision hormone therapy, and patient-centered care models—ensuring long-term growth and improved outcomes for millions worldwide.